Global Human Combination Vaccines Market 2017-2021 - Product Image

Global Human Combination Vaccines Market 2017-2021

  • ID: 4312793
  • Report
  • Region: Global
  • 86 pages
  • TechNavio
OFF
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 5

FEATURED COMPANIES

  • Daiichi Sankyo
  • GlaxoSmithKline
  • Merck
  • Sanofi
  • Serum Institute of India
  • Takeda Pharmaceuticals
  • MORE
A vaccine is made up of inactive, partially killed or dead viruses, to stimulate the immune system against the pathogenic virus and produce antibodies against it. Vaccines are injected or orally administered. Animal vaccines provide immunity to the animal body against pathogens. They are composed of attenuated or dead virus strains and can be administered via the intramuscular, intradermal, or oral route. Similarly, human vaccines are composed of inactivated or live attenuated virus particles and provide immunity to the human body against different pathogens and can be administered via the intramuscular, intradermal, oral, and subcutaneous route. The modern human vaccines are mostly composed of inactivated virus strains.

The report forecasts that the global Human Combination Vaccines market to grow at a CAGR of 8.56% during the period 2017-2021.

Covered in this report:

The report covers the present scenario and the growth prospects of the global Human Combination Vaccines market for 2017-2021. To calculate the market size, the report considers the sales of both branded and generic versions of human combination vaccines.

The market is divided into the following segments based on geography:
  • Americas
  • APAC
  • EMEA
This report, Global Human Combination Vaccines Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion operating in this market.

Key vendors:
  • GlaxoSmithKline
  • Merck
  • Sanofi
Other prominent vendors:
  • Daiichi Sankyo
  • Serum Institute of India
  • Takeda Pharmaceuticals
Market drivers:
  • Rise in cases of infectious diseases
  • For a full, detailed list, view this report
Market challenges:
  • Requirement of cold chain logistics
  • For a full, detailed list, view this report
Market trends:
  • Government-sponsored programs
  • For a full, detailed list, view this report
Key questions answered in this report:
  • What will the market size be in 2021 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?
You can request one free hour of the analyst’s time when you purchase this market report. Details are provided within the report.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Daiichi Sankyo
  • GlaxoSmithKline
  • Merck
  • Sanofi
  • Serum Institute of India
  • Takeda Pharmaceuticals
  • MORE
Part 01: Executive summary

Part 02: Scope of the report

Part 03: Research Methodology

Part 04: Introduction
  • Market outline
Part 05: Human combination vaccines: An overview
  • Need for development of combination vaccines
  • Technical challenges faced during formulation of combination vaccines
  • Strategies for developing human combination vaccines
Part 06: Key clinical trials

Part 07: Market landscape
  • Market overview
  • Market size and forecast
  • Five forces analysis
Part 08: Market segmentation by vaccine type
  • Human combination inactivated vaccines
  • Human combination live attenuated vaccines
Part 09: Geographical segmentation
  • Human combination vaccines market in Americas
  • Human combination vaccines market in EMEA
  • Human combination vaccines market in APAC
Part 10: Decision framework

Part 11: Drivers and challenges
  • Market drivers
  • Market challenges
Part 12: Market trends
  • Government-sponsored programs
  • Growing interest toward R&D of newer vaccines
  • More focus on emerging countries
  • Public–private initiatives
  • Threat of bioterrorism
  • Improvements in healthcare infrastructure
Part 13: Vendor landscape
  • Competitive landscape
Part 14: Key vendor analysis
  • GlaxoSmithKline
  • Merck
  • Sanofi
  • Other prominent vendors
Part 15: Appendix

List of abbreviations

List of Exhibits
Exhibit 01: Advantages of human combination vaccines
Exhibit 02: Marketed human combination vaccines: Overview
Exhibit 03: Pipeline molecule based on vendors
Exhibit 04: Product pipeline
Exhibit 05: Pipeline analysis of key clinical trials
Exhibit 06: Global human combination vaccines market: Snapshot
Exhibit 07: Global human combination vaccines market 2016-2021 ($ millions)
Exhibit 08: Opportunity analysis in global human combination vaccines market
Exhibit 09: Five forces analysis
Exhibit 10: Human combination vaccines market by vaccine type
Exhibit 11: Global human combination vaccine market share by vaccine type 2016
Exhibit 12: Human combination inactivated vaccines market 2016-2021 ($ millions)
Exhibit 13: Human combination live attenuated vaccines market 2016-2021 ($ millions)
Exhibit 14: Global human combination vaccines market by geography 2016 and 2021
Exhibit 15: Global human combination vaccines market revenue by geography 2016-2021 ($ millions)
Exhibit 16: Global human combination vaccines market share by geography 2016-2021
Exhibit 17: Market scenario in Americas
Exhibit 18: Human combination vaccines market in Americas 2016-2021 ($ millions)
Exhibit 19: Market scenario in EMEA
Exhibit 20: Human combination vaccines market in EMEA 2016-2021 ($ millions)
Exhibit 21: Market scenario in APAC
Exhibit 22: Human combination vaccines market in APAC 2016-2021 ($ millions)
Exhibit 23: Total number of children aged 0-5 years in US (millions)
Exhibit 24: Trends in population growth in developing regions
Exhibit 25: Competitive structure analysis of global human combination vaccines market 2016
Exhibit 26: GlaxoSmithKline: Key highlights
Exhibit 27: GlaxoSmithKline: Strength assessment
Exhibit 28: GlaxoSmithKline: Strategy assessment
Exhibit 29: GlaxoSmithKline: Opportunity assessment
Exhibit 30: Merck: Key highlights
Exhibit 31: Merck: Strength assessment
Exhibit 32: Merck: Strategy assessment
Exhibit 33: Merck: Opportunity assessment
Exhibit 34: Sanofi: Key highlights
Exhibit 35: Sanofi: Strength assessment
Exhibit 36: Sanofi: Strategy assessment
Exhibit 37: Sanofi: Opportunity assessment
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5

FEATURED COMPANIES

  • Daiichi Sankyo
  • GlaxoSmithKline
  • Merck
  • Sanofi
  • Serum Institute of India
  • Takeda Pharmaceuticals
  • MORE
New Research Report - Global Human Combination Vaccines Market 2017-2021

Other Prominent Vendors in the market are: Daiichi Sankyo, Serum Institute of India, and Takeda Pharmaceuticals.

Commenting on the report, an analyst from the research team said: “The latest trend gaining momentum in the market is government-sponsored programs. In the past, various diseases have been eradicated globally due to continuous efforts by governments to develop effective combination vaccines and implement proper immunization programs. Vaccines are the cornerstone of the fight against various communicable diseases, which can be proven by the success of smallpox eradication, the drastic decrease in polio cases during the past few decades, the progress toward tetanus eradication, and the decrease in measles mortality rate. Despite such initiatives, infectious diseases remain one of the major causes of deaths worldwide.”

According to the report, one of the major drivers for this market is rise in cases of infectious diseases. Infectious diseases are one of the most common causes of illnesses and deaths worldwide. The presence of microbes and their ability to multiply and adapt to changing populations, environments, and technologies create an ongoing threat to public health. In developing countries, the influence of infectious diseases is often devastating, leading to decreased survival rates, particularly in the pediatric population, and impeding opportunities for economic growth and development.

Further, the report states that one of the major factors hindering the growth of this market is requirement of cold chain logistics. Cold chain logistics required for the storage of vaccines is a key challenge hindering the growth of global human combination vaccine markets, leading to lower acceptability among end-users. Combination vaccines should be stored in cold temperatures to retain their efficacy. They are likely to lose potency if the temperature drops below 2°C or shoots above 8°C. Care should be taken to avoid storing vaccines at freezing temperature as it will destroy vaccines, making them unfit for use. This loss of effectiveness is irreversible, leading to wastage of vaccines and related resources.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
5 of 5
  • GlaxoSmithKline
  • Merck
  • Sanofi
  • Daiichi Sankyo
  • Serum Institute of India
  • Takeda Pharmaceuticals
Note: Product cover images may vary from those shown
6 of 5
Note: Product cover images may vary from those shown
Adroll
adroll